CRISPR Therapeutics AG
CRSP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRSP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRSP
CRISPR Therapeutics AG is a biotech company focused on developing gene-editing based therapies using its CRISPR/Cas9 platform, with one approved product (CASGEVY) partnered with Vertex and a pipeline spanning hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo programs.
Key risk: Early-stage pipeline uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 10 clinical trials for CRISPR Therapeutics AG.
CRISPR Therapeutics AG is a biotech company focused on developing gene-editing based therapies using its CRISPR/Cas9 platform, with one approved product (CASGEVY) partnered with Vertex and a pipeline spanning hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo programs.
- CRISPR Therapeutics has one approved product, CASGEVY (exagamglogene autotemcel), partnered with Vertex, for sickle cell disease and beta-thalassemia [sec_mda · as of 2026-08-03].
- The company reported cash & equivalents of $291.3M as of 2026-06-30 [sec].
- Total revenue for the latest period was $10.2M, with a net loss of $91.2M as of 2026-06-30 [sec].
- Pipeline includes clinical-stage programs in immuno-oncology (CTX112, CTX131), regenerative medicine (CTX211 for type 1 diabetes), and in vivo gene editing (CTX310 for cardiovascular disease) [sec · filed 2025-04-16].
- The company expects existing cash to fund operations for at least the next 24 months, but notes the need for additional financing to support long-term development and commercialization [sec_mda · as of 2026-08-03].
What works
- CRISPR Therapeutics has a commercially approved product, CASGEVY, in partnership with Vertex, providing a validated platform and potential revenue stream [sec_mda · as of 2026-08-03].
- The company has a diversified pipeline across multiple therapeutic areas, including hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo gene editing, reducing single-program risk [sec · filed 2025-04-16].
- Strong cash position of $291.3M as of 2026-06-30 provides a runway of at least 24 months for ongoing operations [sec_mda · as of 2026-08-03].
What to weigh
- Most programs are still in early stages of research and development, with uncertain outcomes and no guarantee of additional marketing approvals beyond CASGEVY [sec_mda · as of 2026-08-03].
- The company has a history of net losses, with a net loss of $91.2M as of 2026-06-30, and expects to continue incurring operating expenses that may increase [sec] [sec_mda · as of 2026-08-03].
- CRISPR Therapeutics will require additional financing to support long-term clinical development and commercialization, and its ability to generate revenue and achieve profitability depends on multiple factors including successful development and regulatory approvals [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
CASGEVY has received marketing approvals in certain jurisdictions.
“Although we and our partner, Vertex, have received marketing approvals for CASGEVY in certain jurisdictions, we cannot guarantee we and Vertex will receive additional marketing approvals for CASGEVY or we will receive marketing approvals for our other product candidates in the future.”
SEC MD&A · August 3, 2026
The company expects existing cash to fund operations for at least 24 months.
“we expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditures for at least the next 24 months without giving effect to any additional proceeds we may receive under our license agreements and collaborations, including with Vertex, and any other capital raising transactions we may complete.”
SEC MD&A · February 12, 2026
The pipeline includes clinical trials for CTX112, CTX131, CTX211, and CTX310.
“trial of CTX112 in adult patients with systemic lupus erythematosus to include systemic sclerosis and inflammatory myositis in a basket study. o Clinical trials for CTX131 in both solid tumors and hematologic malignancies are ongoing. Regenerative Medicine : • Progress in regenerative medicine continues with the ongoing clinical trial for CTX211 in type 1 diabetes, along with the development of next-generation programs. In vivo : • Advancing wholly-owned and partnered programs, including in vivo gene editing programs for both rare and common diseases. o Cardiovascular disease ▪ Clinical trial of CTX310 targeting angiopoietin-related protein 3 (ANGPTL3) in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, or severe hyper”
SEC filings · April 16, 2025
Risks & what to watch (4)›
Key risks
- Early-stage pipeline uncertainty — Most programs are in early research/development; outcome is uncertain and cannot estimate actual costs to complete [sec_mda · as of 2026-08-03].
- Need for additional financing — Company will need additional financing to support long-term development and commercialization [sec_mda · as of 2026-08-03].
- Dependence on regulatory approvals — No guarantee of additional marketing approvals for CASGEVY or other candidates [sec_mda · as of 2026-08-03].
- History of net losses — Company has incurred net losses and expects operating expenses to increase [sec] [sec_mda · as of 2026-08-03].
What to watch
- Progress of clinical trials for CTX112 (lupus), CTX131 (tumors), CTX211 (type 1 diabetes), and CTX310 (cardiovascular) [sec · filed 2025-04-16].
- Any additional marketing approvals for CASGEVY in new jurisdictions [sec_mda · as of 2026-08-03].
- Updates on financing activities to support long-term development [sec_mda · as of 2026-08-03].
- Partnered program developments, including with Vertex for Duchenne muscular dystrophy and myotonic dystrophy type 1 [sec_mda · as of 2025-05-06].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CRISPR Therapeutics AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CRISPR Therapeutics AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
81.3 months
D/E 0.52 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
0 buys · 11 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
490
Total value held
$2.97B
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 11,313,623 | $538.2M |
| blackrock, inc. | 7,680,073 | $365.3M |
| state street corp | 3,982,500 | $189.4M |
| geode capital management, llc | 2,377,164 | $113.1M |
| vanguard capital management llc | 2,285,086 | $108.7M |
| fmr llc | 1,954,694 | $93.0M |
| amova asset management americas, inc. | 1,853,875 | $88.2M |
| sumitomo mitsui trust group, inc. | 1,853,875 | $88.2M |
| ubs group ag | 1,762,530 | $83.8M |
| susquehanna international group, llp | 1,647,106 | $78.4M |
Showing top 10 of 490 institutional holders of CRISPR Therapeutics AG. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 26.7%
- Days to cover
- 12.9
- Shares short
- 22,484,150
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRSP short interestGovernance
Frequently asked questions
What is the AI investment thesis for CRISPR Therapeutics AG?
CRISPR Therapeutics AG is a biotech company focused on developing gene-editing based therapies using its CRISPR/Cas9 platform, with one approved product (CASGEVY) partnered with Vertex and a pipeline spanning hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo programs.
What is CRISPR Therapeutics AG's lead drug candidate?
CRISPR Therapeutics AG's most advanced tracked candidate is CASGEVY (Approved) for Severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
Who is the CEO of CRISPR Therapeutics AG?
Dr. Samarth Kulkarni Ph.D. is the chief executive officer of CRISPR Therapeutics AG (CRSP).
Where is CRISPR Therapeutics AG headquartered?
CRISPR Therapeutics AG (CRSP) is headquartered in Zug, Switzerland.
What therapeutic areas does CRISPR Therapeutics AG focus on?
CRISPR Therapeutics AG develops therapies across Oncology, Rare Disease, Gene Therapy, Immunology, Cardiovascular, Metabolic, Dermatology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.